# FXS6837 for the Treatment for IgAN Patients（Longterm Study）

> **NCT07750665** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Primary IgAN

## Interventions

- **DRUG:** FXS6837 Capsule

## Key facts

- **NCT ID:** NCT07750665
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2029-11-13
- **Final completion:** 2030-01-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07750665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07750665, "FXS6837 for the Treatment for IgAN Patients（Longterm Study）". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07750665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*